ArticleThe American Journal of dermatopathology2012
p53 staining correlates with tumor type and location in sebaceous neoplasms.
Article in The American Journal of dermatopathology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 47 citations in OpenAlex.
- Establishment and Characterization of Three Human Ocular Adnexal Sebaceous Carcinoma Cell Lines.International journal of molecular sciences · 2024Article
- NGS Analysis Confirms CommonInternational journal of molecular sciences · 2021Article
- Expression and Significance of AQP3 in Cutaneous Lesions.Analytical cellular pathology (Amsterdam) · 2021Article
- Whole-exome sequencing for ocular adnexal sebaceous carcinoma suggests PCDH15 as a novel mutation associated with metastasis.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020Article
- Ocular sebaceous gland carcinoma: an update of the literature.International ophthalmology · 2019Review
- Principles and approaches for reproducible scoring of tissue stains in research.Laboratory investigation; a journal of technical methods and pathology · 2018Review
- Cell of origin and mutation pattern define three clinically distinct classes of sebaceous carcinoma.Nature communications · 2018Article
- Expression of p16 and p53 in Intraepithelial Periocular Sebaceous Carcinoma.Ocular oncology and pathology · 2015Article
- Periocular sebaceous gland carcinoma: A comprehensive review.Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society · 2013Article
- Immunoexpression and prognostic role of p53 in different subtypes of epithelial ovarian carcinoma.Journal of biomedical research · 2012Article
- A Case of External Auditory Canal Sebaceous Carcinoma: Literature Review and Treatment Discussion.Biomedicine hubArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
Abstract
Sebaceous neoplasms are commonly considered in their relationship to the Muir-Torre syndrome and the now well-documented loss of DNA mismatch repair proteins leading to microsatellite instability. However, sebaceous neoplasms showing microsatellite instability comprise only a subset of this group of tumors, and thus, alternative tumorigenic mechanisms must exist. This article explores the relationship of p53, a tumor suppressor implicated in other cutaneous malignancies, and sebaceous neoplasia. We examined 94 sebaceous tumors from 92 patients. Tumors with strong nuclear p53 staining were significantly associated with the diagnosis of sebaceous carcinoma compared with benign sebaceous lesions, most notably for periocular carcinomas. Importantly, nuclear mismatch repair protein expression was intact in all lesions showing p53 alterations, suggesting that p53 dysfunction may represent a divergent pathway in the molecular pathogenesis of these tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.